Cristiane Decat Bergerot, Phd answers the question How should we deal with the psychological burden of mRCC? at the 2017 Kidney Cancer Association symposium in Miami, FL.
Author: Editor
Bernard Escudier, Gustave Roussy, Villejuif, FRANCE answers the question How should we treat brain metastases from RCC? at the 2017 Kidney Cancer Association symposium in Miami, FL.
Hans Hammers MD, PhD UT Southwestern asks the question How should we Incorporate Radiotherapy in RCC Management? at the 2017 Kidney Cancer Association symposium in Miami, FL.
James Brugarolas, M.D., Ph.D. Chair, CDMRP Kidney Cancer Research Program Programmatic Panel discusses the CDMRP Kidney Cancer Research Program at the 2017 Kidney Cancer Association symposium in Miami, FL.
Igor Kuzmin, Ph.D. Translational Research Program (TRP) DCTD, NCI trp.cancer.gov asks the question Applying for a SPORE Grant: How to Improve Your Odds?
Tian Zhang, MD Assistant Professor of Medicine Duke Cancer Institute discusses VEGF TKI/immunotherapy combinations will become the standard of care soon at the 2017 Kidney Cancer Association symposium in Miami, FL.
Bradley A McGregor, MD Clinical Director Lank Center for Genitourinary Oncology Dana Farber Cancer Institute discusses TKI Monotherapy Still has a Role in mRCC Front-Line Therapy at the 2017 Kidney Cancer Association symposium in Miami, FL.
Brian I. Rini, M.D. Department of Solid Tumor Oncology Cleveland Clinic Taussig Cancer Center highlights Ipi / Nivo is the New Standard of Care in mRCC at the 2017 Kidney Cancer Association symposium in Miami, FL.
Jianjun Gao, MD, PhD Assistant Professor Genitourinary Medical Oncology of MD Anderson outlines a Discussion of Correlatives Associated with Presurgical Nivolumab + – Bevacizumab or Ipilimumab Trial in mccRCC at the 2017 Kidney Cancer Association symposium in Miami, FL.
Lauren C. Harshman, MD discusses EA8143 PROSPER RCC: The Potential For Discovery through Correlatives at the 2017 Kidney Cancer Association symposium in Miami, FL.
Brian Shuch, MD of the Yale School of Medicine discusses the Biomarker Analysis of MET Alterations and Papillary Subtype in S1500 at the 2017 Kidney Cancer Association symposium in Miami, FL.
Mark Larkin, Director, Vitaccess gives an overview of the Kidney Cancer Association Digital Registry at the 2017 Kidney Cancer Association symposium in Miami, FL.
Laurence Albiges of Gustave Roussy, Villejuif, France discusses Non clear cell RCC Bridging Translational Data to the clinic Papillary RCC at the 2017 Kidney Cancer Association symposium in Miami, FL.
Gabriel Malouf, MD of Pitié-Salpêtrière Hospital University Pierre and Marie Curie discusses Collecting Duct Carcinomas at the 2017 Kidney Cancer Association symposium in Miami, FL.
James J. Hsieh MD of Siteman Cancer Center, Washington University discusses how to classify the unclassified renal cell carcinoma at the 2017 Kidney Cancer Association symposium in Miami, FL.
Gilberto de Lima Lopes, MD discusses the Impact of Geographic Distribution on Outcome in Cancer Africa & Asia at the 2017 Kidney Cancer Association Symposium in Miami FL.
Andr̩ P. Fay, MD, PhD, Professor, PUCRS School of Medicine Chief, Medical Oncology Department РHospital Ṣo Lucas da PUCRS discusses the Impact of Geographic Distribution on Outcome in mRCC-Latin America & South America at the 2017 Kidney Cancer Association symposium in Miami, FL.
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center highlights that denosumab now gives clinicians more choices for treating multiple myeloma.
Raje, Noopur MD of the Massachusetts General Hospital Cancer Center discusses the next steps for Denosumab at the Lymphoma-Myeloma 2017 meeting in New York.
Raje, Noopur S., MD from Massachusetts General Hospital Cancer Center asks the question is it possible to switch from one bone targeting agent to another in multiple myeloma?
Raje, Noopur, MD of Massachusetts General Hospital Cancer Center discusses if it is possible to switch from one bone targeting agent to another in Multiple Myeloma?
Robert G. Uzzo, MD of Fox Chase Cancer Center presents his thoughts on the Cost Effectiveness in Renal Cell Carcinoma – What is Value and Who gets to decide? at the 2017 Annual Kidney Cancer Association in Miami, FL
Noopur Raje, MD of Massachusetts General Hospital Cancer Center outlines how the recently released economic analysis of Denosumab v. Zoledronic Acid found that Denosumab was overall more cost effective. Dr. Raje presented these findings at the 2017 Lymphoma-Myeloma meeting in New York.
John L. Gore, MD, MS from the University of Washington discusses Quality Measures in Renal Cell Carcinoma at the Kidney Cancer Association 2017 annual meeting in Miami FL.
Maxine Sun, PhD, MPH of Dana-Farber Cancer Institute discusses the Utility Pitfalls and Perils of Using Secondary Data for RCC Research at the 2017 annual Kidney Cancer Association Symposium in Miami, FL.
Noopur Raje, MD of Massachusetts General Hospital Cancer Center discusses her findings in which Denosumab is favored in newly diagnosed multiple myeloma patients from a recent economic analysis of Denosumab v Zoledronic Acid in Multiple Myeloma at the 2017 Lymphoma and Myeloma meeting in New York.
Nizar M. Tannir, MD Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston accepts the 2017 Kidney Cancer Association’s Eugene P. Schonfeld Memorial Award and gives an emotional and heartfelt lecture entitled “My Journey in Rare Kidney Tumors”.
Walter Stadler, MD of The University of Chicago discusses the Correlatives Associated with Bevacizumab/Atezolizumab at the annual 2017 Kidney Cancer Association symposium in Miami, FL
Andrew Fabiano, MD, is the Director of the Spinal Oncology Center at Roswell Park Cancer Institute. He shares with fellow physicians how to evaluate cancer patients who present with back pain. Dr. Fabiano discusses when to suspect spinal metastatic disease along with imaging and treatment options. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.
Ronald Alberico, MD, Director, Neuroradiology/Head & Neck at Roswell Park Cancer Institute presents for fellow physicians on identifying patients who may benefit from kyphoplasty and vertebroplasty. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.
What is next-generation sequencing and what is its annotation process? Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine, Clinical Chief, Department of Pathology & Laboratory Medicine, shares with physicians. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.
Khurshid Guru, MD, Chair, Department of Urology and Director, Robotic Surgery at Roswell Park Cancer Institute offers advice for physicians about choosing a cancer surgeon, referring patients to the right institution, and how to measure quality of surgery. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.
Gurkamal Chatta, MD, Clinical Chief of Genitourinary Medicine, presents on immuno-oncology, new immunotherapy cancer treatments and how the immune system responds to cancer. This video originally appeared on www.reachmd.com and is jointly presented by Roswell Park Cancer Institute and Prova Education.
Drs. Kunle Odunsi and Richard Koya provide details on a first-of-its-kind cancer immunotherapy clinical trial, available only at Roswell Park.This clinical trial was recently featured in a three-part series on our blog. Part 1: https://goo.gl/bdxjbM Part 2: https://goo.gl/MrmKGm Part 3: https://goo.gl/y2cDJU
Dr. Jack West reviews the key differences between findings that are worthy of clinical research and those that should be broadly adopted as a standard of care in cancer treatment, and differences in practice in academic vs. community practice.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Ji?à Schwarz discusses challenges in the management of essential thrombocythemia. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Andreas Reiter discusses the biology and therapy of eosinophilic neoplasms. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Jean Luc Villeval discusses the mechanisms of bone marrow fibrosis in patients with myelofibrosis. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Radek C. Skoda discusses new mouse models of myeloproliferative neoplasms (MPN). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Astrid Olsnes Kittang discusses the role of the immune system in the pathogenesis of myelodysplastic syndromes (MDS). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Carmen Aanei elucidates recent advances in the understanding of the myelodysplastic syndromes (MDS) microenvironment. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.
Dr. Jack West reviews evidence that a subset of patients with advanced NSCLC demonstrate “hyper-progressing disease” (HPD), worsening cancer at a faster rate, on immune checkpoint inhibitor therapy, more commonly than seen in patients on chemotherapy.
With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Interested in learning more about developing options to treat myeloproliferative neoplasms (MPNs)? Treating MPNs isnt a one-size-fits-all approach, and research done through clinical trials continues to expand the treatment arsenal. MPN experts Dr. Bart Scott of Seattle Cancer Care Alliance and Dr. David Snyder from City of Hope discuss potential new treatment options currently in development and clinical trials. Tune in to hear the latest. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives a quick outline on why he feels T cell Co-Stimulation is important in immuno-oncology
Anti-OX40 has been demonstrated to improve tumor free survival in mice and is now moving past the first Phase 1 study. Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science outlines the what has been seen so far with OX40.
Ludovic Bourre, Director of Scientific Engagement for Crown Bio Science gives an overview of the Phase 1 Study of Anti-OX40 in Patients With Metastatic Advanced Cancer and it’s conclusions.
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
In this presentation from the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, Dr. Alessandro M. Vannucchi discusses the future of experimental therapeutics for the treatment of myeloproliferative neoplasms (MPN). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?specialty=Hematology © 2017 Imedex, LLC.